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Abstract
Background: Ischemic injury triggers inflammatory cascades and changes in the protein synthesis,
neurotransmitters and neuro-hormones in the brain parenchyma that may further amplify the tissue damage. The
“Triage® Stroke Panel”, a biochemical multimarker assay, detects Brain Natriuretic Peptide (BNP), D-Dimers (DD),
Matrix-Metalloproteinase-9 (MMP-9), and S100β protein generating a Multimarker index of these values (MMX). The
aims of this prospective study in consecutive patients with ischemic or hemorrhagic stroke were to assess: 1) the
rate of an increase of biomarkers (BNP, D-dimer, MMP-9 and S-100β) tested with the Triage Stroke Panel; 2) the
correlation between the increase of these biomarkers and functional outcome at 4 months; 3) the risk factors for
the increase of biomarkers.
Methods: The outcome of the study was 120-day mortality and it was compared in patients with Stroke Panel >4
and ≤4. Multiple logistic regression analyses were performed to identify independent predictors for death and for
the increase of biomarkers.
Results: 244 consecutive patients (mean age 73.02 years; 53.7 % males) were included in the study; 210 ischemic
strokes and 34 hemorrhagic strokes. 161/244 (66.0 %) had an increase of biomarkers. At 120 days, 85 patients had
died (34.8 %). Death was seen in 68/161 patients with an increase of biomarkers (42.2 %) compared with 17/83
patients without (20.5 %). Regression logistic analysis found that a Stroke Panel >4 (OR 3.1; 95 % CI 1.5–6.2, p =
0.002) was associated with mortality. The increase of biomarkers was independently predicted by an increase of
PCR on admission (OR 2.9, 95 CI 1.4–6.0, p = 0.003).
Conclusions: An increase of biochemical markers such as BNP, D-Dimers, MMP-9, and S100β tested with a Triage
Stroke Panel (>4) was correlated with mortality at 120 days from stroke onset.
Background
Ischemic injury triggers inflammatory cascades and
changes in the protein synthesis, neurotransmitters and
neuro-hormones in the brain parenchyma that may fur-
ther amplify tissue damage. Inflammation is a key event
in this ischemic cascade after cerebral ischemia and
some inflammatory-related molecules are produced and
secreted in the neurovascular unit, which could activate
immune system in response to cell damage [1]. Inflam-
matory markers to predict outcome would be useful in
the management of ischemic stroke patients as potential
surrogate measures. This is supported by studies showing
elevated inflammatory markers and is associated with final
infarct volume, including TNF-α, IL-6, ICAM-1, MMP-2
and MMP-9 [2]. Matrix metalloproteinase-9 (MMP-9)
belongs to a family of zinc-binding proteolytic enzymes
that are capable of degrading all components of the extra-
cellular matrix including collagen IV, laminin and fibro-
nectin. Cerebral MMP-9 expression has been found to
increase in the early hours after stroke onset and MMP-9
is thought to be a mediator of increased blood–brain bar-
rier permeability and hemorrhagic transformation follow-
ing ischemic stroke [3].
Other biomarker elevations have been associated with
stroke such as Brain Natriuretic Peptide (BNP), D-dimer
and S-100β protein. BNP is a neuro-hormone that has
potent natriuretic, diuretic and vasodilatatory effects.
Elevations of the circulating BNP concentration have been
observed in patients who experienced delayed ischemic
neurological deficits due to cerebral vasospasm following
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subarachnoid hemorrhage [4]. D-dimer is a cross-linked
fibrin degradation product that is released into the
circulation during fibrinolysis. D-dimer elevations have
been observed following ischemic stroke and may be
indicative of stroke progression [5]. S-100β is a calcium-
binding protein that is found in high concentration
within glial cells. Elevations of the circulating S-100β
concentration have been observed following ischemic
stroke and intracranial hemorrhage, and are associated
with infarct size [6, 7].
The Triage Stroke Panel is a rapid, point-of-care
fluorescence immunoassay to be used with the Triage
MeterPlus for the rapid, quantitative measurement of
BNP, fibrin degradation products containing D-dimer,
MMP-9 and S-100β in EDTA-anticoagulated whole
blood or plasma specimens. The test utilizes a propri-
etary algorithm for the automatic calculation of a single
Multimarker Index (MMX) result from the individual
biomarker values. The MMX result is used as an aid in
the assessment and diagnosis of stroke [8, 9].
The aims of this prospective study in consecutive
patients were to assess: 1) the rate of an increase of
biomarkers (BNP, D-dimer, MMP-9 and S-100β) tested
with Triage Stroke Panel in patients admitted for
ischemic or hemorrhagic stroke; 2) the correlation be-
tween the increase of these biomarkers and functional
outcome at 120 days; 3) the risk factors for the in-
crease of biomarkers. This work came from daily
hospital activity, in which patients underwent various
medical tests. For this reason, we did not require
permission from our institution’s Ethics Committee.
All patients provided informed consent before partici-
pation in the study.
Methods
Consecutive patients admitted to the Department of
Neurology of Vittoria Hospital (Italy) with objectively
diagnosed stroke between January 1st, 2006 and April
15th, 2009 were included in this prospective cohort study.
Patients with transient ischemic attack, cerebral venous
thrombosis and subarachnoid hemorrhage on admission
were excluded. All patients were assessed by a neurologist
to determine the diagnosis of stroke (neurological deficit
lasted >24 h) and its pathological and etiological subtypes
[10]. On admission, stroke severity was assessed using the
NIH (National Institute of Health) Stroke Scale. The
NIHSS is a clinical assessment tool that is widely used in
clinical trials and practice to evaluate stroke-related
neurological deficits. It assesses speech, language cogni-
tion, inattention, visual field abnormalities, motor and
sensory impairments, and ataxia. The maximum possible
score, in case of severe stroke, is 42.
The study centre provided stroke unit standard care
for each patient. All patients were monitored for blood
pressure, temperature, glucose level, heart rate and
blood gases in the first days after stroke.
In all patients cerebral Computed Tomography (CT)
examination without contrast was performed on admis-
sion and after 48–72 h from stroke onset to define both
topography and extension of the ischemic or hemorrhagic
lesion. Patients were admitted to the hospital within 12 h
from the stroke onset.
Based on standard templates the size of the lesion was
quantified as: a) lacunar (lesion in the anterior or poster-
ior circulation <1.5 cm), b) non lacunar (lesion in the
anterior or posterior circulation >1.5 cm).
Stroke risk factors
Data was collected on stroke risk factors: age, gender,
history of hypertension (blood pressure of >140/90
mmHg at least twice before stroke or already under
treatment with antihypertensive drugs), history of dia-
betes mellitus (glucose level >126 mg/dL preprandial on
2nd examination, glucose level >200 mg/dL postprandial,
or HbA1c > 8.5 %, or under hypoglycemic treatment),
current cigarette smoking, history of hyperlipidemia (total
cholesterol concentration >200 mg/dL and/or triglyceride
concentration >140 mg/dL the day after admission or
already under lipid lowering therapy), history of symptom-
atic ischemic heart disease (proven myocardial infarction,
history of angina or existence of multiple lesions on thal-
lium heart isotope screen or evidence of coronary disease
on coronary angiography), atrial fibrillation, or previous
stroke/transient ischemic attacks (TIAs). Other baseline
variables that were obtained at admission for each patient
included homocysteinemia (normal values ≤15 μmol/l)
and PCR (normal values ≤10 mg/dL).
All cases had ultrasonography examination of the
carotid and vertebral arteries. The degree of stenosis
on ultrasonography was evaluated on a duplex sonog-
raphy with power Doppler imaging; linear stenosis,
area stenosis and peak systolic velocity (PSV) were
measured in the most stenotic part of the ICA or
vertebral artery [11, 12]. Patients were considered to
have carotid atherosclerosis if at least one vessel had
stenosis ≥50 % or atherosclerotic occlusion. Occlusion
of an artery was defined as an absence of flow and
when there was the presence of a visible plaque, it
was diagnosed to be caused by atherosclerosis.
Evaluation of outcome
Patients were followed up prospectively by face-to face or
telephone interview. Study outcome was 120-day mortal-
ity. The time of occurence and the cause of death were
recorded. The causes of death were divided into: neuro-
logical (recurrence of stroke, status epilepticus, edema,
herniation), cardiovascular (myocardial infarction, heart
failure, sudden death, other cardiovascular disease) and
Iemolo et al. Immunity & Ageing  (2016) 13:19 Page 2 of 6
other causes (pneumonia, cancer, pulmonary embolus and
other causes).
Measurement of biomarkers with Triage Stroke Panel
The analysis of the biochemical markers (BNP, D-Dimers,
MMP-9, S 100 B, MMX) was done by Sandwich-
Fluorescence-Immunoassay-Technology of the so-called
Triage® Stroke Panel using blood from an EDTA sample
taken within 15 min after admission.
Principles of the test procedure
The test procedure involves the addition of several drops
of an EDTA whole blood or plasma specimen to the
sample port on the Test Device. After addition of the
sample, the cells are automatically separated from the
plasma via a filter contained in the Test Device. The
sample reacts with fluorescent antibody conjugates
within the reaction chamber and flows down the Test
Device detection lane by capillary action. Complexes of
each fluorescent antibody conjugate are captured on
discrete zones resulting in binding assays that are
specific for each biomarker. The Test Device is inserted
into the Triage MeterPlus (hereafter referred to as
Meter) and results are measured and displayed on the
screen. These results are then presented as a single
composite MMX result that is calculated automatically.
This composite MMX result is the test result that is
used as an aid in the diagnosis and assessment of ische-
mic stroke [9]. All analyte concentrations and the MMX
result are stored in the Meter memory and are available
on demand. The MMX result reportable range is 0 to
10. The manufacturer’s recommended cutoffs are 1.3
and 5.9. Using these cutoffs the interpretation is as fol-
lows: MMX results less than or equal to 1.3 represent a
low probability of stroke; MMX results greater than 1.3
are considered abnormal and suggest the need for
further evaluation; MMX results greater than 5.9 repre-
sent a high probability of stroke. However, it is recom-
mended that each laboratory should determine if these
cutoffs are appropriate for the patient population that is
to be evaluated. We have used a score of > 4 because our
statistical analysis detects that values higher than 4 cor-
respond with a greater degree of disability and increased
mortality.
Statistical analysis
A receiver operating characteristic (ROC) curve was
applied to determine a cut-off point of the panel that
could best predict the occurrence of death within 120
days. After the determination of cut-off point, out-
comes in patients with Stroke Panel >4 and ≤4 were
compared by Χ2 test. The first step of analysis was
aimed at identifying predictors of adverse outcome
(death) at 120 days including biomarkers tested with
Triage Stroke Panel. Univariate tests were used to
compare clinical characteristics on admission, preex-
isting risk factors for stroke and CT findings in com-
parison to patients who died. All variables (age, sex,
vascular risk factors, stroke severity on admission,
PCR and Stroke Panel > 4) were subjected to multiple
logistic regression analysis to identify independent
predictors for death.
The second step of analysis was aimed at identifying
predictors of the increase of biomarkers (Stroke Panel > 4)
among baseline findings. Univariate tests were applied to
compare clinical characteristics on admission, preexisting
risk factors for stroke and CT findings to patients with or
without an increase of biomarkers. All variables were
subjected to multiple logistic regression analysis to iden-
tify independent predictors for the increase of biomarkers.
Data was analyzed with the SPSS/PC Win package
19.0 [13].
Results
Incidence of an increase of biomarkers (Stroke panel > 4)
244 consecutive patients (mean age 73.02 years; 53.7 %
males) were included in the study; 210 patients had
ischemic stroke and 34 patients hemorrhagic stroke.
Among 244 patients included in the analysis, 161 (66.0 %)
had an increase of biomarkers.
Influence of an increase of biomarkers on adverse
outcome
At 120 days, 85 patients had died (34.8 %). The causes
of death were neurological in 21 patients, cardiovascular
in 9 patients, other causes in 4 and unknown in 51
patients. In these last cases, by interviewing family mem-
bers and examining clinical documents, it has not been
possible to obtain adequate information about the causes
of death. In Table 1, the characteristics of the patients
alive and deceased are summarized.
The ROC curve evidenced that a Stroke Panel >4
predicted the occurrence of death at 120 days [area
under the curve: 0.62 (95 % CI 0.55–0.69], p = 0.002)
with a sensitivity of 80 % and a specificity of 42 %
(Fig. 1).
Death was seen in 68/161 patients with an increase of
biomarkers (42.2 %) compared with 17 of the 83 patients
without an increase of biomarkers (20.5 %). Multivariate
regression analysis found that a high NIHSS score on
admission (OR 1.08; 95 % CI 1.02–1.14, p = 0.005),
history of ischemic heart disease (OR 2.2; 95 % CI 1.1–
4.5, p = 0.029), an increase of PCR (OR 2.8; 95 % CI 1.4–
5.3, p = 0.002) and a Stroke Panel >4 (OR 3.1; 95 % CI
1.5–6.2, p = 0.002) were associated with adverse outcome
(Table 2).
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Table 1 Characteristics of the deceased or alive patients at 120 days
Risk factors Total (n = 244) Alive patients (n = 159) Deceased patients (n = 85) P
Age (mean) 73.02 ± 13.39 72.66 ± 14.63 73.69 ± 10.73 0.5
Sex male 131 (53.7 %) 87 (54.7 %) 44 (51.8 %) 0.6
Hypertension 155 (63.5 %) 98 (61.6 %) 57 (67.1 %) 0.4
Diabetes mellitus 71 (29.1 %) 48 (30.2 %) 23 (27.1 %) 0.6
Hypercholesterolemia 37 (15.2 %) 26 (16.3 %) 11 (12.9 %) 0.5
Hypertrygliceridemia 16 (6.5 %) 11 (6.9 %) 5 (5.9 %) 1.0
Current smoking 20 (8.2 %) 12 (7.5 %) 8 (9.4 %) 0.6
TIA history 8 (3.3 %) 5 (3.1 %) 3 (3.5 %) 1.0
Stroke recurrence 44 (18.0 %) 31 (19.5 %) 13 (15.3 %) 0.4
Ischemic heart disease 69 (28.3 %) 40 (25.1 %) 29 (34.1 %) 0.08
Atrial fibrillation 10 (4.1 %) 6 (3.8 %) 4 (4.7 %) 0.7
Carotid atherosclerosis 27 (11.1 %) 19 (12.0 %) 8 (9.4 %) 0.6
Ischemic stroke (qualifying event) 210 (86.1 %) 140 (88.1 %) 70 (82.3 %) 0.2
Non-lacunar stroke 120 (49.2 %) 73 (45.9 %) 47 (52.3 %) 0.04
NIHSS on admission (mean) 8.78 ± 6.22 7.79 ± 5.92 10.14 ± 6.37 0.001
Hyperhomocysteimenia 106 (43.4 %) 65 (40.9 %) 41 (48.2 %) 0.2
PCR increase 98 (40.2 %) 51 (30.1 %) 47 (55.3 %) 0.001
Stroke Panel >4 161 (66.0 %) 93 (58.5 %) 68 (80.0 %) 0.001
Fig. 1 a Stroke Panel >4 predicted the occurrence of dead at 120 days; area under the curve 0.62 (95 % CI 0.55–0.69), p = 0.002
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Independent predictors of an increase of biomarkers
The characteristics of patients with and without an in-
crease of inflammatory biomarkers are summarized in
Table 3.
At logistic regression analysis, an increase of biomarkers
was independently predicted by an increase of PCR on
admission (OR 2.9, 95 CI 1.4–6.0, p = 0.003).
Discussion
In this study, we found that an increase of biochemical
markers as BNP, D-Dimers, MMP-9, S and 100β tested
with a Triage Stroke Panel (>4) was correlated with mor-
tality at 120 days from stroke onset.
According to a significant increase of markers of in-
flammation, thrombosis and cellular death as well as
myelin damage within 24 h from stroke onset this
point-of-care immunoassay (Triage Stroke Panel®) has
been developed to improve the reliability of the clin-
ical diagnosis of stroke. Unfortunately, neither one
marker nor combination of all markers was of signifi-
cant benefit in acute stroke diagnostics. DWI-MRI is
still the procedure with the highest diagnostic quality
in case of acute cerebral ischemia [8]. Although the
diagnostic accuracy of the current panel is clearly imper-
fect, the Triage Stroke Panel seems to have prognostic
implications. Until now no study had been focusing on
the MMX value as an index of poor prognosis in 120 days
and the different parameters, separately studied, did not
Table 2 Results of multivariate analysis (mortality at 120 days was the dependent variable)
P Odds
ratio
95,0% Confidence IntervaI for OR
Lower Upper
Sex M ,231 ,672 ,351 1,288
Age ,564 ,993 ,970 1,017
History of TIA ,967 ,965 ,182 5,124
Recurrent stroke ,474 ,744 ,331 1,672
Hypertension ,318 1,395 ,726 2,681
Diabetes mellitus ,869 1,060 ,532 2,111
Ipercholesterolemia ,875 ,923 ,344 2,480
Ipertrigliceridemia ,891 1,099 ,286 4,224
Current smoking ,243 2,003 ,625 6,424
Ischemic heart disease ,029 2,212 1,085 4,509
Alcohol ,884 ,863 ,118 6,304
NIHSS on admission ,005 1,080 1,023 1,140
Atherosclerosis ,829 1,121 ,399 3,148
Stroke Panel >4 ,002 3,078 1,511 6,271
Hyperhomocisteinemia ,559 1,229 ,616 2,454
PCR increase ,002 2,795 1,470 5,312
Vitamin B12 ,734 ,875 ,405 1,888
Ischemic stroke ,485 ,733 ,307 1,751
Table 3 Characteristics of the patients with Triage Stroke
Panel > 4





Age (mean) 72.7 ± 13.3 73.7 ± 13.5 0.5
Sex male 92 (57.1 %) 39 (47.0 %) 0.1
Hypertension 94 (58.3 %) 61 (73.5 %) 0.025
Diabetes mellitus 43 (26.7 %) 28 (33.7 %) 0.3
Hypercholesterolemia 25 (15.5 %) 12 (14.4 %) 1.0
Hypertrygliceridemia 11 (6.8 %) 5 (5.9 %) 1.0
Current smoking 14 (8.7 %) 6 (7.2 %) 0.8
Stroke recurrence 27 (16.8 %) 17 (20.5 %) 0.4
Ischemic heart disease 49 (30.4 %) 30 (36.1 %) 0.4
Atrial fibrillation 7 (4.3 %) 3 (3.6 %) 1.0
Carotid atherosclerosis 16 (9.9 %) 11 (13.2 %) 0.6
Non-lacunar stroke 85 (52.8 %) 35 (42.2 %) 0.1
NIHSS on admission (mean) 8.7 ± 6.2 9.0 ± 6.2 0.7
Hyperhomocysteimenia 74 (45.9 %) 32 (38.5 %) 0.2
PCR increase 77 (47.8 %) 21 (25.3 %) 0.001
Mortality 68 (42.2 %) 17 (20.5 %) 0.001
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provide the same results [14–17]. Interestingly, aside from
S100β, which is a marker of astrocyte activation, the
biomarkers in this stroke panel are not specific to central
nervous system tissues. Thus, although the majority of the
markers used in this panel are not specific for cerebral
ischemia, they represent different components of the
ischemic cascade and when used in conjunction, they pro-
vide complementary information in the prognosis of
stroke. In fact, these biomarkers may be elevated in the
setting of medical comorbidities. For example, elevated
levels of BNP are associated with congestive heart failure
[18] and D-dimer [19] is elevated in any clinical circum-
stance in which both clot formation and subsequent
fibrinolysis are increased, including deep venous throm-
bosis, pulmonary embolism, disseminated intravascular
coagulation, acute myocardial infarction, surgery, and
trauma. For these reasons, the Triage Stroke Panel could
have more efficacy in defining stroke outcome than stroke
diagnosis and its results should not be used as absolute
evidence for cerebral ischemia. Patients who are experien-
cing a heart attack, patients who are candidates for renal
dialysis or have had renal dialysis and patients with heart
failure may have elevated MMX results. Results should be
interpreted along with clinical findings and other test
results. In 17 of the 83 patients without an increase of
biomarkers, we have not observed the ischemic cascade
and a rise of MMX, because the size of the lesion was
modest and there were no significant comorbidities able
to increase the values of biomarkers. Death has probably
occurred for other causes or due to a re-stroke. Although
ROC curve gave significant results, sensitivity and specificity
values were minimally significant. Other limitations that it is
necessary to mention are the residual confounding, the
source of collection of data and the lack of MRI data.
Conclusions
The current study demonstrates the feasibility of incorpor-
ating a biomarker-based point-of-care algorithm with read-
ily available clinical data to aid in the early evaluation of
outcome in patients with stroke. In the patient’s manage-
ment, this data can greatly influence the approach to
rehabilitation therapy, because this test can show us which
patients will benefit most from this therapy since the early
degree of the disease.
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